{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
M006
(2009)
Source URL:
First approved in 1997
Source:
NDA021184
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 332
(2017)
Source URL:
First approved in 1997
Source:
Topex 60 Second Fluoride FoamSpearmint by Dentsply LLC. Professional Division Trading as Sultan Healthcare
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
ANDA074760
(2003)
Source URL:
First approved in 1997
Source:
21 CFR 333C
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NaturVet ArthriSoothe by The Garmon Corporation
(1997)
Source URL:
First approved in 1997
Source:
NaturVet ArthriSoothe by The Garmon Corporation
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
First approved in 1997
Source:
NADA141079
Source URL:
Class:
MIXTURE
Conditions:
Eprinomectin is a mixture of two homologues, eprinomectin B1a (90%) and eprinomectin B1b (10%). The drug is indicated for the treatment of gastrointestinal roundworms in cattle. Eprinomectin acts by binding to glutamate-gated chloride ion channels that leads to paralysis and death of the parasite.
Status:
Possibly Marketed Outside US
Source:
PRENATAL PLUS IRON by Blenheim Pharmacal, Inc.
(2010)
Source URL:
First approved in 1997
Source:
NDA021184
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2011)
Source URL:
First approved in 1996
Source:
NDA020428
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 334
(2021)
Source URL:
First approved in 1996
Source:
Armour Thyroid by Allergan, Inc.
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NCT03350217: Phase 4 Interventional Completed Procedural Bleeding
(2017)
Source URL:
First approved in 1996
Source:
NDA206185
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
M020
(2022)
Source URL:
First approved in 1996
Source:
Strovite Forte Caplet by Everett Laboratories, Inc.
Source URL:
Class:
MIXTURE